Sat, Apr 19, 2014, 1:03 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Feb 19, 2009 7:02 PM Flag

    THLD has all the ingredients to be a huge winner

    Show us the PR or other data specifying the "horrible results" as a single agent. They aren't even done with the PI single agent trial, so there is no final data. They have offered some preliminary data that shows surprising results as a single agent. Why surprising? Because the drug is not expected to cure cancer on its own - it only attacks the hypoxic regions of the tumor, leaving the rest untreated, so it will really only be in the combo trials that TH-302 proves its real worth. In the pre-clinical work, TH-302 did worse as a single agent when compared against the currently approved standard chemo agents. But in combination, TH-302 generated never before seen cure rates in several cancer models. As the CEO stated in the recent presentation, they were not expecting to see much efficacy in the PI single agent trials, so the fact that they have some major tumor response rates is significant.

 
THLD
3.83-0.19(-4.73%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT